Taysha Gene Therapies, Inc. (TSHA) Financials
Annual revenue, profitability and per-share results for Taysha Gene Therapies, Inc., as reported in SEC filings.
Revenue • FY2025
$9.77M
▲ 17.3%YoY
Net income • FY2025
-$109M
▼ 22.1%YoY
Diluted EPS • FY2025
-$0.34
▲ 5.6%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $9.77M | -$109M | — | -$0.34 | -$93.83M | -1130.7% | +17.3% |
| FY2024 | $8.33M | -$89.3M | — | -$0.36 | -$81.6M | -1097.5% | -46.1% |
| FY2023 | $15.45M | -$111.57M | — | -$0.96 | -$76.89M | -468.8% | +517.6% |
| FY2022 | $2.5M | -$166.01M | — | -$3.78 | -$109.01M | -6492.7% | — |
Figures as reported in Taysha Gene Therapies, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a TSHA filing.
Get an email when TSHA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.